Role of sex on psychological distress, quality of life, and coping of patients with advanced colorectal and non-colorectal cancer.
Anxiety
Colorectal cancer
Depression
Gastrointestinal cancer
Sex
Journal
World journal of gastrointestinal oncology
ISSN: 1948-5204
Titre abrégé: World J Gastrointest Oncol
Pays: China
ID NLM: 101532470
Informations de publication
Date de publication:
15 Oct 2022
15 Oct 2022
Historique:
received:
25
04
2022
revised:
24
05
2022
accepted:
25
08
2022
entrez:
31
10
2022
pubmed:
1
11
2022
medline:
1
11
2022
Statut:
ppublish
Résumé
Patients with advanced gastrointestinal cancer must cope with the negative effects of cancer and complications. To evaluate psychological distress, quality of life, and coping strategies in patients with advanced colorectal cancer compared to non-colorectal cancer based on sex. A prospective, transversal, multicenter study was conducted in 203 patients; 101 (50%) had a colorectal and 102 (50%) had digestive, non-colorectal advanced cancer. Participants completed questionnaires evaluating psychological distress (Brief Symptom Inventory-18), quality of life (EORTC QLQ-C30), and coping strategies (Mini-Mental Adjustment to Cancer) before starting systemic cancer treatment. The study included 42.4% women. Women exhibited more depressive symptoms, anxiety, functional limitations, and anxious preoccupation than men. Patients with non-colorectal digestive cancer and women showed more somatization and physical symptoms than subjects with colorectal cancer and men. Men with colorectal cancer reported the best health status. The degree of disease acceptance in gastrointestinal malignancies may depend on sex and location of the primary digestive neoplasm. Future interventions should specifically address sex and tumor site differences in individuals with advanced digestive cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with advanced gastrointestinal cancer must cope with the negative effects of cancer and complications.
AIM
OBJECTIVE
To evaluate psychological distress, quality of life, and coping strategies in patients with advanced colorectal cancer compared to non-colorectal cancer based on sex.
METHODS
METHODS
A prospective, transversal, multicenter study was conducted in 203 patients; 101 (50%) had a colorectal and 102 (50%) had digestive, non-colorectal advanced cancer. Participants completed questionnaires evaluating psychological distress (Brief Symptom Inventory-18), quality of life (EORTC QLQ-C30), and coping strategies (Mini-Mental Adjustment to Cancer) before starting systemic cancer treatment.
RESULTS
RESULTS
The study included 42.4% women. Women exhibited more depressive symptoms, anxiety, functional limitations, and anxious preoccupation than men. Patients with non-colorectal digestive cancer and women showed more somatization and physical symptoms than subjects with colorectal cancer and men. Men with colorectal cancer reported the best health status.
CONCLUSION
CONCLUSIONS
The degree of disease acceptance in gastrointestinal malignancies may depend on sex and location of the primary digestive neoplasm. Future interventions should specifically address sex and tumor site differences in individuals with advanced digestive cancer.
Identifiants
pubmed: 36310711
doi: 10.4251/wjgo.v14.i10.2025
pmc: PMC9611434
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2025-2037Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Dr. Pacheco-Barcia reports grants from FSEOM and grants from Astra Zeneca during the conduct of the study; other from Eisai, other from Merck, other from Eli Lilly, other from Advanced accelerator applications, a Novartis company, grants from FSEOM and Merck, other from Roche, other from Eli Lilly, other from Bristol-Myers Squibb, other from Merck, other from Amgen, other from Merck Sharp and Dhome, other from Nutricia, other from Roche, other from Bayer, other from Amgen, other from Esteve, other from Eli Lilly, other from Roche, other from Bristol-Myers Squibb, grants from Ayuda Clínico Formativa AECC 2020, grants from FSEOM, outside the submitted work.
Références
Psychooncology. 2018 Sep;27(9):2172-2179
pubmed: 29856903
Psychooncology. 2016 Aug;25(8):891-7
pubmed: 26582649
J Natl Cancer Inst. 2021 Nov 2;113(11):1551-1560
pubmed: 33837791
Cancer. 2012 Oct 1;118(19):4824-32
pubmed: 22294480
Palliat Med. 2020 Dec;34(10):1436-1446
pubmed: 32781931
BMC Palliat Care. 2020 Sep 17;19(1):144
pubmed: 32943037
JAMA Oncol. 2018 Jul 1;4(7):1003-1006
pubmed: 29800044
Cancer. 2018 Jun 15;124(12):2621-2628
pubmed: 29624635
Int J Clin Oncol. 2005 Dec;10(6):411-7
pubmed: 16369745
Eur J Cancer. 2017 Jan;70:87-98
pubmed: 27907852
Oncol Nurs Forum. 2020 Sep 1;47(5):586-594
pubmed: 32830804
J Pers Med. 2021 Jan 30;11(2):
pubmed: 33573202
Support Care Cancer. 2019 Sep;27(9):3421-3429
pubmed: 30661203
J Gastrointest Cancer. 2022 Jun;53(2):245-252
pubmed: 33417199
World J Gastroenterol. 2015 May 7;21(17):5167-75
pubmed: 25954090
Eur J Clin Pharmacol. 2013 Dec;69(12):2073-81
pubmed: 23989300
Rev Esp Enferm Dig. 2012 Dec;104(11):584-91
pubmed: 23368650
Clin Pharmacol Ther. 2002 Dec;72(6):638-47
pubmed: 12496745
Br J Cancer. 2000 Nov;83(10):1261-7
pubmed: 11044347
Int J Clin Health Psychol. 2020 Jan-Apr;20(1):71-80
pubmed: 32021621
Psychooncology. 2009 Aug;18(8):866-74
pubmed: 19061195
PLoS One. 2013 Jul 05;8(7):e68077
pubmed: 23861851
J Affect Disord. 2017 Aug 15;218:59-65
pubmed: 28458117
J Affect Disord. 2012 Dec 10;141(2-3):343-51
pubmed: 22727334
Biomol Ther (Seoul). 2018 Jul 1;26(4):335-342
pubmed: 29949843
Res Integr Peer Rev. 2016 May 03;1:2
pubmed: 29451543
Int J Oncol. 2014 Jan;44(1):319-26
pubmed: 24247204
Ann Surg Oncol. 2016 Dec;23(13):4344-4351
pubmed: 27469120
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Psychooncology. 2006 Feb;15(2):143-59
pubmed: 15880638
Cancer Chemother Pharmacol. 2013 Feb;71(2):361-70
pubmed: 23139054
Cancer. 2009 Nov 15;115(22):5349-61
pubmed: 19753617
Dan Med J. 2012 Jun;59(6):A4444
pubmed: 22677242
Lancet. 1999 Apr 3;353(9159):1119-26
pubmed: 10209974
Invest Educ Enferm. 2017 Oct;35(3):320-329
pubmed: 29767912
Int J Clin Health Psychol. 2021 Jan-Apr;21(1):100185
pubmed: 33363578
Indian J Psychol Med. 2012 Apr;34(2):119-23
pubmed: 23162185
Arch Intern Med. 2000 Jul 24;160(14):2101-7
pubmed: 10904452
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Psychooncology. 2011 Feb;20(2):165-72
pubmed: 20217657
Health Psychol. 1998 Sep;17(5):459-69
pubmed: 9776005
J Gastrointest Oncol. 2017 Feb;8(1):81-88
pubmed: 28280612
JAMA. 2016 Nov 8;316(18):1863-1864
pubmed: 27802482
Prz Gastroenterol. 2016;11(2):96-103
pubmed: 27350836
J Gastrointest Oncol. 2011 Jun;2(2):77-84
pubmed: 22811834
J Clin Pharmacol. 2015 Nov;55(11):1303-12
pubmed: 25975718
Langenbecks Arch Surg. 2020 Feb;405(1):71-80
pubmed: 32002628
J Psychosom Res. 2008 Dec;65(6):549-52
pubmed: 19027443
J Urol. 2013 Apr;189(4):1470-4
pubmed: 23206422
Br J Cancer. 2000 Jun;82(11):1860-2
pubmed: 10839302
Womens Health (Lond). 2011 Mar;7(2):213-26
pubmed: 21410347
Dis Colon Rectum. 2010 Jan;53(1):57-64
pubmed: 20010352
Surg Oncol. 2019 Dec;31:26-32
pubmed: 31493647
PLoS One. 2017 Sep 20;12(9):e0183288
pubmed: 28931010
Psychol Med. 2010 Nov;40(11):1797-810
pubmed: 20085667
Eur J Gastroenterol Hepatol. 2016 Jul;28(7):831-5
pubmed: 26928565
Qual Life Res. 2022 Jun;31(6):1859-1869
pubmed: 34928470